Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
12.76
-0.22 (-1.69%)
At close: Apr 1, 2025, 4:00 PM
11.86
-0.90 (-7.03%)
After-hours: Apr 1, 2025, 4:38 PM EDT
Company Description
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.
The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 13, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Sean Brynjelsen |
Contact Details
Address: 21925 W. Field Parkway, Suite 235 Deer Park, Illinois 60010-7278 United States | |
| Phone | 847 787 7361 |
| Website | etonpharma.com |
Stock Details
| Ticker Symbol | ETON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001710340 |
| CUSIP Number | 29772L108 |
| ISIN Number | US29772L1089 |
| Employer ID | 37-1858472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sean E. Brynjelsen | President, Chief Executive Officer and Director |
| David C. Krempa | Chief Business Officer |
| Danka Radosavljevic | Senior Vice President of Quality and Operations |
| Scott Grossenbach | Senior Vice President of Sales Operations |
| Kevin Guthrie | Executive Vice President of Commercial Operations |
| Ipek Erdogan-Trinkaus | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 14, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 8-K/A | [Amend] Current report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | 8-K | Current Report |
| Feb 6, 2025 | 8-K | Current Report |